Help the Future of Cancer Treatment

Volunteering for a clinical trial is a contribution to the future of medicine that only you can make.

Quantitative MRI for Myelofibrosis

Primary Investigator
Luker, Gary
Status
OPEN TO ACCRUAL
Phase
NA
NCT Number
NCT01973881
UM Number
2014.034
Age Group
Adults
Management Group
CTSU - Oncology
Oncology Group
Hematological Malignancies
ID (Protocol)
13301
Secondary Protocol No
HUM00077505
Scope
Unspecified
Sponsor Type
National
Disease Site
Ill-Defined Sites
Summary
This study is for the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis.

Eligibility: Inclusion Criteria
  •   Male /female subjects over the age of 18
  •   Diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.
  •   No contraindications to MRI
  •   Able to undergo MRI without anesthesia
Exclusion Criteria
  •   Patients with pacemakers or other implanted magnetic devices that may malfunction or move because of the strong magnetic field inside the MRI room and scanner.
  •   Any prior adverse event associated with MRI that is not related to injection of contrast agents or other medicines.